Jennifer Martin is a Professor of Medicine at UCLA David Geffen School of Medicine. She focuses on topics related to farm management, ranching, and organic farming, often exploring the intersection of agriculture and health at various events and conferences. Her insights and expertise have been featured in CBS News, Investment Executive, Pop Culture, Insider, and several other prominent publications.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jennifer's articles predominantly focus on promoting deals and providing guides for gift purchases, particularly related to specific events and products. If you have insights into upcoming sales, promotions, or new product launches aligned with the themes of her coverage such as seasonal events like Labor Day 2023 or Amazon Prime Day 2023, reaching out to Jennifer could be beneficial.
Pitching ideas around promotional offers, discounts, and reviews of consumer goods linked to major shopping events can provide value based on her focused coverage area. Additionally, if you represent a company offering significant discounts or special deals during these occasions (Labor Day 2023), presenting this information in a concise and appealing manner may capture Jennifer’s attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Beverley Brown, Charlotte L Hall, Olivia Hastings, Sophie S Hall, Jacob Andrews, Jennifer Martin, Sonal Marner, Rebecca Woodcock, Kelly Marie Prentice
Principles of Industry-Academic Partnerships Informed by Digital Mental Health Collaboration: Mixed Methods Study Abstract
By: Jennifer Martin
Adapting to market shifts, elevating compliance, and strengthening connections across the industry
Maybe it's the pace of change across the auto finance industry. Maybe it's the growing complexity of the regulatory environment. Or maybe it's the fact that the NAF Association Annual Conference is celebrating a major milestone.
By: Étienne Chatelut, Joseph Ciccolini, Dirk Jan, Jeroen Hendrikx, Oncopole Claudius Regaud, Jennifer Martin
Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as targeted therapies or more recently as immune checkpoint inhibitors (ICIs). The fact that only some patients benefit from these drugs poses the usual question in the field of onco‐hematology: that of the benefit of individual dosing and the potential of therapeutic drug monitoring (TDM) to carry out this individualization. However, Mabs present unique pharmacological characteristics for TDM, and the pharmacokinetic–pharmacodynamic relationship observed should be interpreted differently than that observed for conventional drugs and small molecules. This pharmacology practice review has been summarized from a public debate between the authors at the International TDM and Clinical Toxicology meeting in Banff, 2020, regarding the potential roles of TDM in the Mab/ICI setting.
By: Jennifer Martin, Sophie S. Hall, Alexia Jeayes, Christopher Partlett, Charlotte L. Hall, Helen Henshaw, Nikita Rattu, Emily Shoesmith, Nihr Nottingham
Abstract Decentralised clinical trials (DCTs) may help address underrepresentation in digital mental health research, but their effectiveness in reaching underserved populations is unclear.
